Adagio Medical Holdings, Inc (ADGM) AI Stock Analysis

Adagio Medical Holdings, Inc. is a medical technology company focused on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. Its solutions target conditions such as atrial fibrillation and ventricular tachycardia. The company's product portfolio includes the iCLAS atrial ultra-low temperature ablation (ULTA) catheter and system, the vCLAS ventricular ULTC catheter, and Cryopulse pulsed field cryoablation catheters. Founded in 2011, the company is headquartered in Laguna Hills, California, and employed 41 people as of October 16, 2026.

Revenue for Adagio Medical has remained limited, moving from $270,000 in FY2021 to $269,000 in FY2024, resulting in a 3-year revenue CAGR of -0.1%. During FY2024, revenue fell 10.3%, gross margin stood at -620.1%, operating margin was -23226.8%, and net income totaled -$53.8M with an EPS of -$10.54. R&D expenses in FY2024 were $4.6M, down from $15.4M in FY2023. Over the trailing twelve months ended June 30, 2026, revenue stood at $137,000 with quarterly revenue growing 75.6% year-over-year.

As of June 30, 2026, Adagio Medical held $7.7M in cash and short-term investments against total debt of $26.0M, resulting in net debt of $18.3M. Total assets stood at $33.9M, and the current ratio was 1.41. Shareholders' equity was negative at -$415,000. In FY2024, operating cash flow was -$29.5M and free cash flow was -$31.1M, while capital expenditures reached $374,000 in FY2025.

Adagio Medical trades at a price-to-sales multiple of 205.8x and an enterprise-value-to-revenue multiple of 370.2x, significantly higher than the median of its US-listed Healthcare peers, which carries a price-to-sales multiple of 4.1x. Its price-to-book ratio is 2.9x. The stock closed at $0.10 on October 16, 2026, down 93.3% over the past year compared to a 16.8% return for the S&P 500 (SPY).

Wall Street analysts maintain 2 Strong Buy and 1 Buy ratings on ADGM, with zero Hold or Sell ratings. The mean price target is $3.33, representing a 3267.0% increase over the last close of $0.10. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$1.09 on revenue of $0, followed by an EPS estimate of -$1.16 on $1.5M in revenue for the next fiscal year. The company beat EPS estimates in 2 of the last 4 quarters, and its next earnings date is November 11, 2026.

This page is an AI-written research summary of Adagio Medical Holdings, Inc (ADGM). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ADGM income statement, ADGM balance sheet, ADGM key metrics, ADGM analyst forecast, ADGM chart. See the ADGM stock overview for the latest quote and news.